Ally Financial Inc. Buys Shares of 18,000 Amgen, Inc. (AMGN)

Ally Financial Inc. acquired a new position in shares of Amgen, Inc. (NASDAQ:AMGN) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 18,000 shares of the medical research company’s stock, valued at approximately $2,632,000.

Several other large investors have also recently made changes to their positions in AMGN. FMR LLC increased its stake in shares of Amgen by 11.3% in the fourth quarter. FMR LLC now owns 40,789,786 shares of the medical research company’s stock worth $5,963,875,000 after buying an additional 4,144,154 shares in the last quarter. Asset Management One Co. Ltd. increased its position in Amgen by 426.2% in the fourth quarter. Asset Management One Co. Ltd. now owns 1,331,811 shares of the medical research company’s stock worth $194,885,000 after buying an additional 1,078,691 shares during the period. State Street Corp increased its position in Amgen by 2.8% in the fourth quarter. State Street Corp now owns 34,308,673 shares of the medical research company’s stock worth $5,016,268,000 after buying an additional 919,966 shares during the period. Russell Investments Group Ltd. bought a new position in Amgen during the fourth quarter worth approximately $117,903,000. Finally, Morgan Stanley increased its position in Amgen by 8.0% in the third quarter. Morgan Stanley now owns 8,678,786 shares of the medical research company’s stock worth $1,447,708,000 after buying an additional 639,410 shares during the period. 79.04% of the stock is currently owned by institutional investors.

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Shares of Amgen, Inc. (NASDAQ:AMGN) opened at 169.24 on Tuesday. The firm has a market cap of $124.64 billion, a PE ratio of 16.53 and a beta of 1.15. Amgen, Inc. has a 1-year low of $133.64 and a 1-year high of $184.21. The stock has a 50 day moving average of $171.88 and a 200 day moving average of $159.85.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Thursday, February 2nd. The medical research company reported $2.89 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.79 by $0.10. The business earned $5.97 billion during the quarter, compared to analyst estimates of $5.75 billion. Amgen had a net margin of 33.59% and a return on equity of 29.42%. The business’s revenue was up 7.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.61 earnings per share. Equities research analysts anticipate that Amgen, Inc. will post $12.31 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 8th. Investors of record on Wednesday, May 17th will be paid a $1.15 dividend. The ex-dividend date is Monday, May 15th. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.72%. Amgen’s dividend payout ratio (DPR) is presently 44.92%.

Your IP Address:

AMGN has been the topic of a number of recent analyst reports. Robert W. Baird reaffirmed a “neutral” rating and issued a $165.00 target price on shares of Amgen in a research report on Friday. Cann reaffirmed an “outperform” rating on shares of Amgen in a research report on Wednesday, February 22nd. Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and issued a $189.00 target price on shares of Amgen in a research report on Tuesday, March 14th. Bank of America Corp raised shares of Amgen from a “neutral” rating to a “buy” rating and increased their target price for the company from $156.68 to $192.00 in a research report on Wednesday, February 1st. Finally, Royal Bank of Canada set a $190.00 target price on shares of Amgen and gave the company a “buy” rating in a research report on Wednesday, January 4th. One analyst has rated the stock with a sell rating, ten have issued a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $187.41.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

5 Day Chart for NASDAQ:AMGN

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2024681/ally-financial-inc-buys-shares-of-18000-amgen-inc-amgn.html

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.